KSF News, Updates, & Insights

Plaintiffs Win Class Certification in Esperion Therapeutics Securities Litigation

On May 31, 2020 the Honorable R. Steven Whalen certified a class of shareholders in Dougherty v. Esperion Therapeutics, Inc. et al, No. 2:16-cv-10089, a securities fraud class action pending in the United States District Court for the Eastern District of Michigan. The allegations of the case involve Defendants’ materially misleading statements and omissions concerning a cardiovascular outcomes trial for the Company’s lead drug candidate. The Court, recommending appointment of KSF as co-class counsel alongside another firm, noted “counsel’s diligent prosecution of this case to date, including a win in the Sixth Circuit,” and highlighted KSF’s “significant collective experience in class litigation.” Judge Whalen recommended a certified Class including: “All persons who purchased or otherwise acquired the common stock of Esperion Therapeutics, Inc. between August 18, 2015 and September 28, 2015 (inclusive) and were damaged thereby.”